scholarly journals Bladder Preservation by Internal Iliac Arterial Infusion Chemotherapy and Irradiation in T3 Bladder Carcinoma Patients over the Age of 70 Years

2000 ◽  
Vol 192 (4) ◽  
pp. 249-258 ◽  
Author(s):  
Senji Hoshi ◽  
Ichiro Shintaku ◽  
Ken-ichi Suzuki ◽  
Toshiko Takahashi ◽  
Yasuhiro Kaihou ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Arterial Infusion ◽  
Bladder Preservation ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy ◽  
Internal Iliac

Effect of Internal Iliac Artery Embolization Combined With Arterial Infusion Chemotherapy On Serum VEGF, HGF and IL-6 in Advanced Cervical Cancer

2021 ◽  
Vol 7 (4) ◽  
pp. 538-545
Author(s):  
Xiaoru Li ◽  
Yan Zhao ◽  
Tao Yu
Keyword(s):  
Cervical Cancer ◽  
Internal Iliac Artery ◽  
Observation Group ◽  
Advanced Cervical Cancer ◽  
Artery Embolization ◽  
Arterial Infusion ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy ◽  
Internal Iliac ◽  
Internal Iliac Artery Embolization

This study aimed to investigate the effect of internal iliac artery embolization combined with arterial infusion chemotherapy on serum VEGF, HGF and IL-6 in advanced cervical cancer. A total of 120 cases of patients with advanced cervical cancer and admitted to Binzhou Center Hospital from January 2014 to March 2016 were selected as research subjects. Among them, 59 patients received arterial infusion chemotherapy were enrolled in the control group, and 61 patients received arterial infusion chemotherapy combined with internal iliac artery embolization were included in the observation group. Treatment efficacy, serum VEGF, HGF and IL-6 expression, KPS score and QOL score, incidence of adverse reactions and 3-year survival rate of the two groups were recorded and compared. The result showed that the therapeutic effect of the observation group was significantly higher than that of the control group (P<0.05). The expression of serum VEGF, HGF and IL-6, KPS score and QOL score in the two groups were significantly improved after treatment, with more significant improvement in the observation group (P<0.05). There were no significant differences in the incidence of adverse reactions between the two groups (P>0.05). And the 3-year survival rate of the observation group was significantly higher than that of the control group (P<0.05). In conclusion, arterial infusion chemotherapy combined with internal iliac artery embolization has a better effect than arterial infusion chemotherapy alone in treating patients with advanced cervical cancer. It can effectively prolong the survival of patients, along with good safety, which is worthy of clinical promotion

Two Patients With N3 Bladder Cancer Successfully Treated by Internal Iliac Arterial Infusion Chemotherapy and Irradiation

2001 ◽  
Vol 24 (1) ◽  
pp. 87-90 ◽  
Author(s):  
Senji Hoshi ◽  
Ken-Ichi Suzuki ◽  
Ichiro Shintaku ◽  
Katsuko Sato ◽  
Yasuhiro Kaihou ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Arterial Infusion ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy ◽  
Internal Iliac

Internal Iliac Arterial Infusion Chemotherapy for Rabbit Invasive Bladder Cancer

1997 ◽  
Vol 4 (5) ◽  
pp. 493-499 ◽  
Author(s):  
Senji Hoshi ◽  
Hauping Mao ◽  
Toshiko Takahashi ◽  
Kenichi Suzuki ◽  
Masato Nose ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Arterial Infusion ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy ◽  
Internal Iliac

scholarly journals Successful Treatment of a Large Superficial Bladder Cancer with Neoadjuvant Arterial Infusion Chemotherapy: A Case Report

2018 ◽  
Vol 11 (2) ◽  
pp. 383-387
Author(s):  
Hiroshi Kano ◽  
Sotaro Miwa ◽  
Kiyoshi Koshida ◽  
Keiichi Kawai
Keyword(s):  
Bladder Cancer ◽  
Bladder Tumor ◽  
Superficial Bladder Cancer ◽  
Medical Center ◽  
Operation Time ◽  
Arterial Infusion ◽  
Bladder Preservation ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy ◽  
Tumor Volume Reduction

We present a case in which neoadjuvant arterial infusion chemotherapy was effective in treating a large superficial bladder cancer. A 50-year-old male was admitted to the Kanazawa Medical Center with the complaint of dizziness. The patient exhibited severe anemia, and his computer tomography showed a large bladder tumor. Cystoscopy revealed a large papillary tumor. Magnetic resonance imaging showed no muscle invasion and no metastasis. To avoid a prolonged operation time and excessive blood loss, we performed neoadjuvant arterial infusion chemotherapy for tumor volume reduction before transurethral resection of the bladder tumor (TUR-BT). The arterial infusion chemotherapy was performed twice, and the tumor size gradually reduced from 275 to 28 cm3. After neoadjuvant chemotherapy, TUR-BT was safely performed without blood transfusion. The tumor was staged as T1 with G1. This is the first report demonstrating that neoadjuvant arterial infusion chemotherapy is effective in treating large superficial bladder cancer and is a possible strategy for bladder preservation.

scholarly journals Stent placement combined with intraluminal radiofrequency ablation and hepatic arterial infusion chemotherapy for advanced biliary tract cancers with biliary obstruction: a multicentre, retrospective, controlled study

2021 ◽  
Author(s):  
Qing Gou ◽  
Lingeng Wu ◽  
Wei Cui ◽  
Zhiqiang Mo ◽  
Dejin Zeng ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Biliary Tract ◽  
Stent Placement ◽  
Biliary Obstruction ◽  
Hepatic Arterial Infusion ◽  
Hepatic Arterial Infusion Chemotherapy ◽  
Efficacy And Safety ◽  
Arterial Infusion ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy

Abstract Objective To evaluate the efficacy and safety of stent placement combined with intraluminal radiofrequency ablation (intra-RFA) and hepatic arterial infusion chemotherapy (HAIC) for patients with advanced biliary tract cancers (Ad-BTCs) and biliary obstruction (BO). Methods We retrospectively reviewed data for patients with Ad-BTCs and BO who underwent stent placement with or without intra-RFA and HAIC in three centres between November 2013 and November 2018. The stent patency time (SPT), overall survival (OS), and adverse events (AEs) were analysed. Results Of the 135 enrolled patients, 64 underwent stent placement combined with intra-RFA and HAIC, while 71 underwent only stent placement. The median SPT was significantly longer in the combination group (8.2 months, 95% confidence interval [CI]: 7.1–9.3) than in the control group (4.3 months, 95% CI: 3.6–5.0; p < 0.001). A similar result was observed for OS (combination: 13.2 months, 95% CI: 11.1–16.5; control: 8.5 months, 95% CI: 7.6–9.6; p < 0.001). The incidence of AEs related to biliary tract operation was not significantly different between the two groups (p > 0.05). The most common AE and serious AE related to HAIC were alanine aminotransferase elevation (24/64; 37.5%) and thrombocytopenia (8/64; 12.5%), respectively. All AEs were tolerable, and there was no death from AEs. Conclusions Stent placement combined with intra-RFA and HAIC may be a safe, potential treatment strategy for patients with Ad-BTCs and BO. Key Points • Advanced biliary cancers (Ad-BTCs) with biliary obstruction (BO) can rapidly result in liver failure and cachexia with an extremely poor prognosis. • Stent placement combined with intraluminal radiofrequency ablation and hepatic arterial infusion chemotherapy may be safe and effective for patients with Ad-BTCs and BO. • The long-term efficacy and safety of the combined treatment is promising.

scholarly journals Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma

2021 ◽  
Vol 11 (4) ◽  
pp. 1882
Author(s):  
Takahiro Yamasaki ◽  
Issei Saeki ◽  
Yurika Kotoh-Yamauchi ◽  
Ryo Sasaki ◽  
Norikazu Tanabe ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Vascular Invasion ◽  
Hepatic Arterial Infusion ◽  
Hepatic Arterial Infusion Chemotherapy ◽  
Advanced Hepatocellular Carcinoma ◽  
Arterial Infusion ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy ◽  
Recent Success ◽  
Clinical Benefits

Recent success of systemic therapeutic agents, including combination immunotherapy, could promote a change in the treatment strategy in patients with advanced hepatocellular carcinoma (HCC). Although hepatic arterial infusion chemotherapy (HAIC) is a treatment option for advanced HCC in Japan, it is not recommended by other guidelines. We discuss the clinical benefits of HAIC compared to sorafenib. The clinical benefits of HAIC are as follows: (1) even a patient with Child–Pugh B HCC (7 or 8 points) is a candidate for HAIC (2) Child–Pugh scores barely decline with the use of HAIC compared with sorafenib (3) HAIC is highly effective in patients with vascular invasion compared with sorafenib; and (4) survival in patients receiving HAIC may not be associated with skeletal muscle volume. In contrast, the disadvantages are problems related with the reservoir system. HAIC has clinical benefits in a subpopulation of patients without extrahepatic metastasis with Child–Pugh A HCC and vascular invasion (especially primary branch invasion or main portal vein invasion) or with Child–Pugh B HCC.

Sign in / Sign up

Export Citation Format

Share Document